CARI - Caring for Australasians with Renal Impairment

CHRONIC KIDNEY DISEASE

» Prevention of progression [published 2006]
» Nutrition & growth [published 2005]
» Cardiovascular risk factors [published 2005]
» Vitamin D, calcimimetics & phosphate binders [published 2006]
» Urine protein as diagnostic test [published 2004]
» Evaluation of renal function [published 2005]
» Kidney stones [published 2007]
» Renal Vasculitis [under development]
» Archive of Previous Guidelines

DIALYSIS

» Acceptance onto dialysis [published 2005]
» Biochemical & Haematological targets [published 2006]
» Dialysis adequacy [published 2005]
» Peritonitis treatment & prophylaxis [published 2004]
» Vascular access[under development]
» Archive of Previous Guidelines

TRANSPLANTATION

» Deceased kidney donor suitability [published 2005]
» CMV disease & kidney transplants [published 2004]
» Calcineurin inhibitors in renal transplantation [published 2007]
» Living kidney donors [under development]
» Archive of Previous Guidelines

For Guideline Writers

Our Sponsors

The CARI Guidlelines project receives financial support from both industry and the Australian Government. Kidney Health Australia and the ANZSN provide guidance and non-financial support.

Amgen Australia (www.amgen.com.au)

Janssen-Cilag Australia (www.janssen-cilag.com.au)

KHA Kidney Health Australia (www.kidney.org.au)

ANZSN Australian and New Zealand Society of Nephrology (www.nephrology.edu.au)

NHMRC National Health and Medical Research Council (Centre for Clinical Research Excellence in Renal Medicine www.ccre.health.usyd.edu.au)

Genzyme Australasia P/L

Roche Products